Cargando…

Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer

Inter-tumor heterogeneity is a result of genomic, transcriptional, translational, and post-translational molecular features. To investigate the roles of protein glycosylation in the heterogeneity of high-grade serous ovarian carcinoma (HGSC), we perform mass spectrometry-based glycoproteomic charact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Jianbo, Hu, Yingwei, Sun, Shisheng, Chen, Lijun, Schnaubelt, Michael, Clark, David, Ao, Minghui, Zhang, Zhen, Chan, Daniel, Qian, Jiang, Zhang, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708455/ https://www.ncbi.nlm.nih.gov/pubmed/33262351 http://dx.doi.org/10.1038/s41467-020-19976-3

Ejemplares similares

Orthogonal Proteomic Platforms and Their Implications for the Stable Classification of High-Grade Serous Ovarian Cancer Subtypes
por: Thomas, Stefani N., et al.
Publicado: (2020)

Mapping the O‐glycoproteome using site‐specific extraction of O‐linked glycopeptides (EXoO)
por: Yang, Weiming, et al.
Publicado: (2018)

Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach
por: Khashaba, Marwa, et al.
Publicado: (2022)

Glycoproteomic Study Reveals Altered Plasma Proteins Associated with HIV Elite Suppressors
por: Yang, Weiming, et al.
Publicado: (2014)

Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging
por: Kassuhn, Wanja, et al.
Publicado: (2021)

Prognostic gene expression signature for high-grade serous ovarian cancer
por: Millstein, J., et al.
Publicado: (2020)

Glycoproteomic analysis identifies human glycoproteins secreted from HIV latently infected T cells and reveals their presence in HIV(+) plasma
por: Yang, Weiming, et al.
Publicado: (2014)

An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors
por: Li, Qing Kay, et al.
Publicado: (2017)

Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma
por: Gilks, C. Blake
Publicado: (2010)

Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging
por: Miyagawa, Chiho, et al.
Publicado: (2023)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer
por: Hillman, R Tyler, et al.
Publicado: (2017)

Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients
por: Jiao, Mi, et al.
Publicado: (2022)

OmicsOne: associate omics data with phenotypes in one-click
por: Zhang, Hui, et al.
Publicado: (2021)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2020)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Molecular Characterization of an Intact p53 Pathway Subtype in High-Grade Serous Ovarian Cancer
por: Hayano, Takahide, et al.
Publicado: (2014)

Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma
por: Shilpi, Arunima, et al.
Publicado: (2019)

The Claudin-Low Subtype of High-Grade Serous Ovarian Carcinoma Exhibits Stem Cell Features
por: Romani, Chiara, et al.
Publicado: (2021)

Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma
por: Hollis, Robert L., et al.
Publicado: (2023)

Protein signatures of molecular pathways in non-small cell lung carcinoma (NSCLC): comparison of glycoproteomics and global proteomics
por: Yang, Shuang, et al.
Publicado: (2017)

Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer
por: Kieffer, Yann, et al.
Publicado: (2020)

Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
por: Zhang, Lu, et al.
Publicado: (2021)

Precision N‐glycoproteomics reveals elevated LacdiNAc as a novel signature of intrahepatic cholangiocarcinoma
por: Li, Jun, et al.
Publicado: (2021)

Differential expression of estrogen receptor subtypes in ovarian high‐grade serous carcinoma and clear cell carcinoma
por: Osaku, Daiken, et al.
Publicado: (2021)

Comparison of Three Glycoproteomic Methods for the Analysis of the Secretome of CHO Cells Treated with 1,3,4-O-Bu(3)ManNAc
por: Mertz, Joseph L., et al.
Publicado: (2020)

A Robust Gene Expression Prognostic Signature for Overall Survival in High-Grade Serous Ovarian Cancer
por: Zhao, Yue, et al.
Publicado: (2019)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer
por: Ahn, Hee-Sung, et al.
Publicado: (2020)

TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer
por: Lecuelle, Julie, et al.
Publicado: (2021)

Oxidatively Modified Proteins in the Serous Subtype of Ovarian Carcinoma
por: Mehrabi, Sharifeh, et al.
Publicado: (2014)

Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer
por: Sun, Yan, et al.
Publicado: (2015)

Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes
por: Way, Gregory P., et al.
Publicado: (2016)

A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer
por: Lo Riso, Pietro, et al.
Publicado: (2020)

Identification of Tumor Antigens and Immune Subtypes of High-grade Serous Ovarian Cancer for mRNA Vaccine Development
por: Wu, Yanxuan, et al.
Publicado: (2023)

Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells
por: Clark, David J., et al.
Publicado: (2016)

Molecular Subtyping of Serous Ovarian Cancer Based on Multi-omics Data
por: Zhang, Zhe, et al.
Publicado: (2016)

Single‐cell transcriptomes reveal heterogeneity of high‐grade serous ovarian carcinoma
por: Hao, Qian, et al.
Publicado: (2021)

TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
por: Qi, Gonghua, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6elafpra0qg354ag9ul4apvt4i